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Sir,
We appreciate the attention given by Drs Dutt, Salvesen,
Greulich, Sellers, Beroukhim and Meyerson to our recent
publication ‘The oncogenic mutation in the pleckstrin homology
domain of AKT1 in endometrial carcinomas’ (Shoji et al, 2009). In
this article, we report a 2% mutational frequency of AKT1 (E17K)
among 101 endometrial carcinomas. We also described that these
two AKT1 mutant tumours do not possess any mutations in
PIK3CA, PTEN and K-Ras. Our report has proposed two issues to
be clarified: (1) Are there any ‘oncogenic’ mutations in other
AKT family members in endometrial carcinomas? (2) Are all
the AKT family mutations mutually exclusive with other PI3
kinase-AKT-activating mutations?
Including the data in their earlier report, Dutt et al (2008)
revealed mutations in AKT2 and AKT3, as well as in AKT1. As for
AKT1 (E17K) mutations, their data and our data are compatible,
showing that AKT1 mutations were detected in 2% of the
endometrioid subtype in endometrial cancer. Compared with
the accumulative data in AKT1 (E17K) mutations, mutations in
AKT2 and AKT3 are not well characterised. Carpten et al (2007)
and Kim et al (2008) reported no E17K mutations in AKT2 and
AKT3 in breast, colorectal, gastric, hepatocellular, lung carcinomas
and acute leukaemias. Davies et al (2008) first reported AKT3
(E17K) mutations in melanoma at 1.5% frequency. Parsons et al
(2005) found two mutations of AKT2 (S302G and R371H) in 204
colorectal cancer samples, and Soung et al (2006) reported one
missense mutation (A377V) and two possible splice-site mutations
in intron 11 of AKT2 in gastric and lung adenocarcinoma.
However, the physiological role of AKT2 mutations, including
those (D399N, R368C and D32H) reported by Dutt et al (2008), has
not been validated yet. In addition, the AKT3 (E438D) mutation
has not been reported in any type of tumours. It is important to
clarify whether these rare AKT2/3 mutations cause an oncogenic
effect in cancer.
We previously reported that PIK3CA mutations frequently
coexist with mutations in PTEN and/or KRAS, and suggested that
the PIK3CA mutation might require another upstream input to
fully activate the PI3K kinase–AKT pathway (Oda et al, 2005,
2008). Their data of coexistent mutations in AKT1 (E17K) and
KRAS (G13D) suggest that the KRAS mutation alone is insufficient
for a full activation of the PI3 kinase–AKT pathway. Their data are
not inconsistent with the hypothesis that the AKT1 (E17K)
mutation and the PIK3CA mutation are mutually exclusive. The
coexistent mutations of AKT3 and PIK3CA in one sample suggest
that some types of AKT mutations (non-E17K) might coexist
with PIK3CA mutations to enhance the activation of the PI3
kinase–AKT pathway. Further analyses are necessary to clarify the
frequency of coexistent mutations in AKT1 (E17K), AKT2/3 and
other mutations.
Their current data and our data suggest that the PI3 kinase–
AKT pathway is prevalently activated in endometrial cancer
through various genetic alterations and their combinations.
Further analyses in AKT, PIK3CA and other PI3 kinase-AKT-
related genes would be helpful to comprehensively understand the
mechanism of activation in this pathway and to use PI3K-targeted
therapies in various types of cancer.
We thank Dr Dutt and colleagues for their recognition of
our work.
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